US009408847B2

(12) **United States Patent**
Doshi et al.

(10) **Patent No.: US 9,408,847 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **COMBINATION THERAPY**

(71) Applicants: **Shivang Doshi**, Cambridge, MA (US); **Sunkyu Kim**, Cambridge, MA (US)

(72) Inventors: **Shivang Doshi**, Cambridge, MA (US); **Sunkyu Kim**, Cambridge, MA (US)

(73) Assignee: **Novartis AG**, Basel (CH)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/646,206**

(22) PCT Filed: **Nov. 25, 2013**

(86) PCT No.: **PCT/US2013/071659**
§ 371 (c)(1),
(2) Date: **May 20, 2015**

(87) PCT Pub. No.: **WO2014/085318**
PCT Pub. Date: **Jun. 5, 2014**

(65) **Prior Publication Data**

US 2015/0306104 A1 Oct. 29, 2015

Related U.S. Application Data

(60) Provisional application No. 61/730,661, filed on Nov. 28, 2012.

(51) **Int. Cl.**
A61K 31/519 (2006.01)
A61K 31/436 (2006.01)
A61K 45/06 (2006.01)

(52) **U.S. Cl.**
CPC ***A61K 31/519*** (2013.01); ***A61K 31/436*** (2013.01); ***A61K 45/06*** (2013.01)

(58) **Field of Classification Search**
CPC A61K 31/519; A61K 31/436
USPC 514/252, 258.1; 544/280
See application file for complete search history.

(56) **References Cited**

FOREIGN PATENT DOCUMENTS

WO 2011/130232 10/2011
WO WO 2011/130232 * 10/2011
WO WO 2011130232 A1 * 10/2011 ..... A61K 31/436

OTHER PUBLICATIONS

Finn, Richard SEt al.: "PD 0332991, a selective cyclin D kinase 4/6 inhibiter, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cncer cell lines in vitro", Breast Cancer Research, Current Science, Vo. 11, No. 5, p. R77, 2009.*
Jose, Baselga Et al.: "EveroLimus +n Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer", New England Journal of Medicine, The Massachusetts Medical Society, vol. 366, No. 6, pp. 520-529, 2012.*
Finn, Richard S Et al.: "PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cncer cell lines in vitro", Breast Cancer Research, Current Science, vol. 11, No. 5, p. R77, 2009.
Jose, Baselga Et al.: "Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer", New England Journal of Medicine, The Massachusetts Medical Society, vol. 366, No. 6, pp. 520-529, 2012.

* cited by examiner

Primary Examiner — Kamal Saeed
Assistant Examiner — Janet L Coppins
(74) *Attorney, Agent, or Firm* — Jennifer Chapman

(57) **ABSTRACT**

The present invention relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is a mTOR inhibitor or a pharmaceutically acceptable salt thereof.

10 Claims, 5 Drawing Sheets